ATE342916T1 - Synthetische hiv gag gene - Google Patents
Synthetische hiv gag geneInfo
- Publication number
- ATE342916T1 ATE342916T1 AT98904971T AT98904971T ATE342916T1 AT E342916 T1 ATE342916 T1 AT E342916T1 AT 98904971 T AT98904971 T AT 98904971T AT 98904971 T AT98904971 T AT 98904971T AT E342916 T1 ATE342916 T1 AT E342916T1
- Authority
- AT
- Austria
- Prior art keywords
- hiv gag
- synthetic
- synthetic hiv
- gag genes
- codons
- Prior art date
Links
- 108700004026 gag Genes Proteins 0.000 title 1
- 108020004705 Codon Proteins 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3785497P | 1997-02-07 | 1997-02-07 | |
GBGB9705040.5A GB9705040D0 (en) | 1997-03-12 | 1997-03-12 | Synthetic HIV GAG genes |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE342916T1 true ATE342916T1 (de) | 2006-11-15 |
Family
ID=26311165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98904971T ATE342916T1 (de) | 1997-02-07 | 1998-02-03 | Synthetische hiv gag gene |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0969862B1 (de) |
JP (1) | JP2001512308A (de) |
KR (1) | KR20000070865A (de) |
CN (1) | CN1252075A (de) |
AT (1) | ATE342916T1 (de) |
AU (1) | AU743616B2 (de) |
CA (1) | CA2280195A1 (de) |
DE (1) | DE69836206T2 (de) |
DK (1) | DK0969862T3 (de) |
EE (1) | EE9900343A (de) |
ES (1) | ES2274566T3 (de) |
IL (1) | IL131131A0 (de) |
NO (1) | NO993810L (de) |
PL (1) | PL335050A1 (de) |
SK (1) | SK106699A3 (de) |
WO (1) | WO1998034640A2 (de) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6492110B1 (en) | 1998-11-02 | 2002-12-10 | Uab Research Foundation | Reference clones and sequences for non-subtype B isolates of human immunodeficiency virus type 1 |
GB9803351D0 (en) * | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
WO2000039302A2 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
AU2487300A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
CA2369119A1 (en) | 1999-03-29 | 2000-05-25 | Statens Serum Institut | Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
CA2369058A1 (en) * | 1999-04-26 | 2000-11-02 | K.U. Leuven Research & Development | Synthetic gene for expressing active retroviral protein in eukaryotes |
CA2378539A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
DE60016765T2 (de) * | 1999-08-25 | 2005-11-24 | Merck & Co., Inc. | Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind |
EP2278022A3 (de) | 1999-11-01 | 2011-05-18 | Novartis Vaccines and Diagnostics, Inc. | Expressionsvektoren, Transfektionssysteme und Verfahren zu deren Verwendung |
US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
US7655774B2 (en) * | 2000-02-18 | 2010-02-02 | University Of Washington | Ancestral and COT viral sequences, proteins and immunogenic compositions |
EP1156112B1 (de) * | 2000-05-18 | 2006-03-01 | Geneart GmbH | Synthetische Gene für gagpol und deren Verwendungen |
GB0014288D0 (en) | 2000-06-10 | 2000-08-02 | Smithkline Beecham Biolog | Vaccine |
NZ523683A (en) * | 2000-07-21 | 2004-08-27 | Glaxo Group Ltd | Codon-optimized papilloma virus sequences |
AU2001292151B2 (en) | 2000-08-17 | 2006-05-04 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US6858590B2 (en) | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
EP1800697B1 (de) | 2001-06-05 | 2010-04-14 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie |
WO2002103024A2 (en) | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
EP1409694A4 (de) | 2001-07-05 | 2006-02-08 | Chiron Corp | Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen |
JP5033303B2 (ja) | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用 |
WO2003012117A1 (en) * | 2001-07-28 | 2003-02-13 | The Secretary Of State For Defence | Dna vaccine |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
FR2845918A1 (fr) * | 2002-10-16 | 2004-04-23 | Pasteur Institut | Preparations immunogenes et vaccinantes a base d'arn |
AU2003235707A1 (en) * | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
RU2356943C2 (ru) | 2003-03-24 | 2009-05-27 | Мерк Энд Ко., Инк. | Молекула нуклеиновой кислоты, кодирующая hpv31 l1, экспрессирующий вектор, клетка-хозяин, вирусоподобная частица и способ ее получения, вакцина, фармацевтическая композиция и способы с их использованием |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
GB0321614D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Vaccines |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
JP5030594B2 (ja) | 2003-12-23 | 2012-09-19 | アルボー ビータ コーポレーション | Hpvの発癌性株に対する抗体およびそれらの使用方法 |
KR101203403B1 (ko) | 2004-03-24 | 2012-11-21 | 머크 샤프 앤드 돔 코포레이션 | 효모에서 hpv 52 l1의 최적화된 발현 |
DE102004037611B4 (de) | 2004-08-03 | 2013-10-02 | Geneart Ag | Induzierbare Genexpression |
CN101072585A (zh) | 2004-11-01 | 2007-11-14 | 诺华疫苗和诊断公司 | 产生免疫应答的组合方法 |
KR101158756B1 (ko) | 2006-12-20 | 2012-06-22 | (주) 에빅스젠 | 코돈 최적화시킨 hiv의 nc 폴리뉴클레오티드, 상기폴리뉴클레오티드를 포함하는 벡터 및 이를 이용한 nc단백질의 생산방법 |
US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
EP2244695A1 (de) | 2007-12-07 | 2010-11-03 | Novartis AG | Zusammensetzungen zur induktion von immunantworten |
TW201029662A (en) | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
AR080027A1 (es) | 2010-01-28 | 2012-03-07 | Glaxo Group Ltd | Proteinas de union a cd127 |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
JP5883443B2 (ja) | 2010-07-22 | 2016-03-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規の抗原結合タンパク質 |
EP3578205A1 (de) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
CA3162352A1 (en) | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
CA2868996A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
JP6211597B2 (ja) | 2012-05-01 | 2017-10-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 新規抗体 |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (de) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynukleotide zur codierung immunmodulierender polypeptide |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP129A (en) * | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
WO1991009869A1 (en) * | 1990-01-05 | 1991-07-11 | Medical Research Council | Hiv-1 core protein fragments |
JPH07505412A (ja) * | 1992-04-14 | 1995-06-15 | ブリティッシュ バイオテック ファーマシューティカルズリミテッド | Ctl応答の誘導 |
NZ262582A (en) * | 1993-01-26 | 1997-10-24 | David B Weiner | Compositions and methods for delivery of genetic material |
US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US5795737A (en) * | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
ES2251734T3 (es) * | 1996-02-22 | 2006-05-01 | MERCK & CO., INC. | Genes sinteticos de hiv. |
US6114148C1 (en) * | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
-
1998
- 1998-02-03 AT AT98904971T patent/ATE342916T1/de not_active IP Right Cessation
- 1998-02-03 CA CA002280195A patent/CA2280195A1/en not_active Abandoned
- 1998-02-03 IL IL13113198A patent/IL131131A0/xx unknown
- 1998-02-03 KR KR1019997007130A patent/KR20000070865A/ko not_active Application Discontinuation
- 1998-02-03 ES ES98904971T patent/ES2274566T3/es not_active Expired - Lifetime
- 1998-02-03 JP JP53490598A patent/JP2001512308A/ja active Pending
- 1998-02-03 DK DK98904971T patent/DK0969862T3/da active
- 1998-02-03 AU AU62711/98A patent/AU743616B2/en not_active Ceased
- 1998-02-03 PL PL98335050A patent/PL335050A1/xx unknown
- 1998-02-03 CN CN98803975A patent/CN1252075A/zh active Pending
- 1998-02-03 EE EEP199900343A patent/EE9900343A/xx unknown
- 1998-02-03 DE DE69836206T patent/DE69836206T2/de not_active Expired - Fee Related
- 1998-02-03 SK SK1066-99A patent/SK106699A3/sk unknown
- 1998-02-03 EP EP98904971A patent/EP0969862B1/de not_active Expired - Lifetime
- 1998-02-03 WO PCT/US1998/002293 patent/WO1998034640A2/en active IP Right Grant
-
1999
- 1999-08-06 NO NO993810A patent/NO993810L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO993810D0 (no) | 1999-08-06 |
CN1252075A (zh) | 2000-05-03 |
SK106699A3 (en) | 2000-06-12 |
EE9900343A (et) | 2000-02-15 |
DE69836206D1 (de) | 2006-11-30 |
KR20000070865A (ko) | 2000-11-25 |
EP0969862B1 (de) | 2006-10-18 |
IL131131A0 (en) | 2001-01-28 |
WO1998034640A2 (en) | 1998-08-13 |
NO993810L (no) | 1999-10-07 |
ES2274566T3 (es) | 2007-05-16 |
DK0969862T3 (da) | 2007-02-12 |
AU743616B2 (en) | 2002-01-31 |
CA2280195A1 (en) | 1998-08-13 |
AU6271198A (en) | 1998-08-26 |
JP2001512308A (ja) | 2001-08-21 |
EP0969862A2 (de) | 2000-01-12 |
WO1998034640A3 (en) | 1998-11-19 |
DE69836206T2 (de) | 2007-08-23 |
PL335050A1 (en) | 2000-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69836206D1 (de) | Synthetische hiv gag gene | |
NZ331161A (en) | Synthetic HIV genes encoding envelope (env) proteins | |
PT1212358E (pt) | Genes sinteticos de papilomavirus humano | |
WO1997048370A3 (en) | Vaccines comprising synthetic genes | |
ATE334216T1 (de) | Impstoff gegen felines immunodefizienz-virus | |
MX9203458A (es) | Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano. | |
WO2003059381A3 (en) | Immunogenic preparations and vaccines on the basis of mrna | |
TR200001835T2 (tr) | Aşı. | |
BR9406007A (pt) | Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano | |
AU3472299A (en) | Rna cancer vaccine and methods for its use | |
AU7690898A (en) | Vectors and methods for immunization or therapeutic protocols | |
WO2002032943A3 (en) | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization | |
AU1013601A (en) | Method of inducing and/or enhancing an immune response to tumor antigens | |
ES2151506T3 (es) | Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos. | |
DE69732029D1 (de) | Dna enthaltende impfstoffen | |
ATE317016T1 (de) | Herstellung rekombinanter künstlicher hefe- chromosome, welche das genom des humanen cytomegalovirus enthalten | |
DE60106222D1 (de) | Herpesviren für die modulation einer immunantwort | |
DE69836485D1 (de) | Hepatitis e-virus aus dem schwein und dessen verwendungen | |
HUP0001857A2 (hu) | Bakteriális plazmidok | |
EA199900726A1 (ru) | Синтетические hiv gag гены | |
ECSP972034A (es) | Genes sinteticos vih | |
EA199800750A1 (ru) | Синтетические гены вич | |
HUP0103871A2 (hu) | Rekombináns CELO-vírus és CELO vírus DNS | |
ES2182340T3 (es) | Oligonucleotidos quimericos y su uso. | |
FI945110A (fi) | Tippuribakteerien rokotteiden valmistusmenetelmä |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0969862 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |